Webcast - Update on the molecular virology and pathogenesis of SARS-CoV-2 and COVID-19

In the rapidly developing field of COVID-19 virology, Professor Darius Moradpour hosts this update to our current understanding of SARS-CoV-2 infection, supported by three world-renowned experts looking at the major challenges that lie ahead.

Although multiple vaccines have now been approved, one of the most important ongoing complications of the SARS-CoV-2 pandemic will be to monitor and adapt to the emergence of new variants. In this webcast, the experts explore current understanding of coronavirus evolution, which can lead to antigenic drift and the potential for immune escape, and discuss the possible implications for transmission and human health.

Looking at the clinical characteristics of SARS-CoV-2 infection, the experts also discuss ongoing progress in the use of antiviral therapy, the evidence around SARS-CoV-2 infection in hepatocytes and liver injury, and special considerations in immunosuppressed patients.


Learning objectives:

  • Understand the evolution of coronaviruses, including antigenic drift and the potential for immune escape
  • Learn about the possible implications for transmission and human health
  • Understand the clinical characteristics of SARS-CoV-2 infection
  • Learn about the currently used antiviral therapy
  • Learn about SARS-CoV-2 infection in hepatocytes and the consequences on liver injury


Target audience:

  • Hepatologists
  • General practitioners
  • Health care professionals
  • Clinical researchers and scientists


Darius Moradpour Darius Moradpour is a Professor of Medicine at the University of Lausanne and the Chief of the Division of Gastroenterology and Hepatology of Lausanne University Hospital in Switzerland. He served as Member of the EASL Governing Board from 2008 to 2011 and as Associate Editor of the Journal of Hepatology from 2014 to 2019. His research focuses on the molecular virology and pathogenesis of hepatitis C and E as well as clinical and translational studies in viral hepatitis and other liver diseases.
Sandra Ciesek Sandra Ciesek is Head of the Institute of Medical Virology at the University Hospital Frankfurt, Germany. She is also Vice Dean for Young Scientists and Diversity at Goethe University in Frankfurt. Professor Ciesek has been significantly involved in research on SARS-CoV-2, the novel coronavirus, and is primarily conducting research on new antiviral targets for the therapy of COVID-19.
Jan Felix Drexler Jan Felix Drexler is Head of the Virus Epidemiology Group and an Associate Professor in the Institute of Virology at Charité – Universitätsmedizin Berlin, Germany. Professor Drexler’s research focuses on the evolution and epidemiology of emerging viruses at the animal–human interface, including uncovering the zoonotic origins of major human viruses like hepatitis A and B virus, as well as developing affordable tests for HIV, hepatitis C virus and yellow fever virus for international public laboratories.
Volker Thiel Volker Thiel is Head of the Division of Virology at the Institute of Virology and Immunology, part of the Federal Food Safety and Veterinary Office in Bern, Switzerland. He is also a Professor and Chair of Veterinary Virology in the Department of Infectious Diseases and Pathobiology at the University of Bern. Professor Thiel’s research interests focus on host-switching pathogens, infectious outbreaks and zoonosis, and he is currently studying the functional characterisation and innate immune response to SARS-CoV-2. He is a member of the World Health Organization’s Workgroup on SARS-CoV-2 Evolution and the Swiss National COVID-19 Science Task Force.